SEC 1746 Potential persons who are to respond to the collection of
(11-02) information contained in this form are not required to respond
unless the form displays a currently valid OMB control number.
OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response...11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
TASCO HOLDINGS INTERNATIONAL, INC.
(Name of Issuer)
________________________________________________________________________________
Common Stock ($0.0001 par value)
(Title of Class of Securities)
876506 20 5
(CUSIP Number)
________________________________________________________________________________
David R. Koos, Chairman & CEO
Bio-Matrix Scientific Group, Inc.
1010 University Avenue, Suite 40
San Diego, California 92103
Telephone 619-227-9192
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
________________________________________________________________________________
July 1, 2006
(Date of Event which Requires Filing of this Statement)
________________________________________________________________________________
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box. [ ]
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss.240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 876506 20 5
________________________________________________________________________________
1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons
(entities only).
Bio-Matrix Scientific Group, Inc., #50-0020556
________________________________________________________________________________
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ...................................................................
(b) ...................................................................
________________________________________________________________________________
3. SEC Use Only ...........................................................
________________________________________________________________________________
4. Source of Funds (See Instructions) PF-OO
________________________________________________________________________________
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
2(d) or 2(e) ...........................................................
________________________________________________________________________________
6. Citizenship or Place of Organization : Delaware
________________________________________________________________________________
Number of 7. Sole Voting Power: 10,000,000 shares of common stock ($0.0001
Shares par value) ..................................................
Beneficially
Owned by 8. Shared Voting Power ..........................................
Each
Reporting 9. Sole Dispositive Power. 10,000,000 shares of common stock
Person With ($0.0001 par value)
10. Shared Dispositive Power .....................................
________________________________________________________________________________
11. Aggregate Amount Beneficially Owned by Each Reporting Person: 10,000,000
shares of common stock ($0.0001 par value)
________________________________________________________________________________
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) .....................................................
________________________________________________________________________________
13. Percent of Class Represented by Amount in Row (11): 78.24%
________________________________________________________________________________
14. Type of Reporting Person (See Instructions)
CO......................................................................
........................................................................
........................................................................
........................................................................
........................................................................
________________________________________________________________________________
Introduction
This constitutes the Schedule 13D filed on behalf of Bio-Matrix Scientific
Group, Inc., a Delaware corporation and relating to the acquisition of
10,000,000 shares of the common stock of Tasco Holdings International, Inc.
acquired upon sale by Bio-Matrix Scientific Group, Inc. of its wholly-owned
subsidiary, Bio-Matrix Scientific Group, Inc., a Nevada corporation
(BMXG-Nevada) to Tasco Holdings International, Inc. The sale of the subsidiary
to Tasco Holdings International, Inc. was accomplished solely in exchange for
the sale of 25,000 shares of the common stock of the subsidiary, BMXG-Nevada.
All of the disclosures set forth in the statements made in this Schedule 13D
remain unchanged.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
________________________________________________________________________________
Date: July 1, 2006
________________________________________________________________________________
Signature: /s/ David R. Koos
________________________________________________________________________________
Name/Title: David R. Koos, Chairman & CEO
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative (other than an executive
officer or general partner of the filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement: provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)